media – Page 427 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Identifying, educating patients are essential to successful peritoneal dialysis programs

Beginning or growing a peritoneal dialysis program requires knowledgeable staff who can reach as many potential patient candidates as possible, according to a speaker at ASN Kidney Week. “A successful PD program is a program that can offer PD to the widest possible range of patients and not only can a successful program offer PD to these patients, but it can maintain these patients on PD to maximally realize their goals of care,” Brendan McCormick, MD, FRCPC, associate professor at the University of Ottawa and medical director of home dialysis at the Ottawa Hospital, said during the meeting, which was held as a virtual event. Nephrologists, nurses and other health care team members can most easily identify potential candidates in chronic kidney disease programs, but it is important to avoid overlooking patients in the hospital, McCormick said. Educating potential candidates is a key component. Effective education requires knowledgeable staff and ...
- Source: drugdu
- 174
- October 29, 2020
educating patients
Real-time data show COVID-19’s massive impact on global emissions

Source: Potsdam Institute for Climate Impact Research (PIK) Summary: While the ongoing coronavirus pandemic continues to threaten millions of lives around the world, the first half of 2020 saw an unprecedented decline in carbon dioxide emissions — larger than during the financial crisis of 2008, the oil crisis of the 1979, or even World War II. Masked Earth photo concept (stock image; elements furnished by NASA). While the ongoing coronavirus pandemic continues to threaten millions of lives around the world, the first half of 2020 saw an unprecedented decline in CO2 emissions — larger than during the financial crisis of 2008, the oil crisis of the 1979, or even World War II. An international team of researchers has found that in the first six months of this year, 8.8 percent less carbon dioxide was emitted than in the same period in 2019 — a total decrease of 1551 million tonnes. The ...
- Source: drugdu
- 341
- October 28, 2020
Covid-19
Hopes rise for approval of coronavirus vaccine by end of year

US expert Dr Anthony Fauci says it should be known by early December if vaccine is safe to roll out Nurses on a Covid-19 ward in Merseyside, north-west England. Healthcare workers and people most at risk will be prioritised for first doses of a vaccine. Photograph: Peter Byrne/PA Hopes are rising that a coronavirus vaccine will be approved by the end of the year, with healthcare workers receiving their first dose in early 2021. Dr Anthony Fauci, the US’s leading expert in infectious diseases, said on Sunday it should be known by the end of November or early December if a vaccine was safe and effective. The Irish government added to the growing optimism that a vaccine would soon be available. “I’m increasingly optimistic, as is government, that we will see a vaccine approved in the next couple of months and that in the first half or first quarter of next ...
- Source: drugdu
- 222
- October 27, 2020
Covid-19
FDA Approves First Treatment for COVID-19

For Immediate Release: October 22, 2020 Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered under the EUA, the FDA revised the EUA for Veklury to authorize the drug’s use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to ...
- Source: drugdu
- 261
- October 26, 2020
Covid-19
Remdesivir becomes first Covid-19 treatment to receive FDA approval

By Maggie Fox, CNN Updated 5:36 PM ET, Thu October 22, 2020 (CNN) The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, said Thursday. It is the first drug to be approved for treating Covid-19. The drug, sold under the brand name Veklury, has been used under emergency use authorization since May. The antiviral has shown, at best, a modest benefit for coronavirus patients. But there is little else available. “In the United States, Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization,” the company said in a statement. “Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.” Earlier this month, a World Health Organization-sponsored global study found remdesivir ...
- Source: drugdu
- 248
- October 23, 2020
Covid-19
UK government signs contract for first coronavirus human challenge studies

By Mick Krever and Phil Black, CNN Updated 4:26 AM ET, Tue October 20, 2020 Why she is volunteering to get infected with Covid-19 03:26 London (CNN) The UK government has signed a contract for the first human challenge studies for the novel coronavirus, in which healthy volunteers are deliberately infected with the virus in a controlled setting, and some receive an experimental vaccine. Up to 19 volunteers at a time will take part in the tests, to be held at the Royal Free Hospital in London, which houses a Biosafety Level 3 ward. They will be run by hVIVO, a medical research company that specializes in running challenge trials, in partnership with Imperial College London. These clinical trials will be a little different from most. For the current Covid-19 vaccine candidates that are in Phase 3 — the final stage of testing — tens of thousands of volunteers are given an experimental ...
- Source: drugdu
- 284
- October 22, 2020
CORONAVIRUS coronavirus vaccine
Will COVID-19 Get Worse in the Winter?

BY ELIZABETH HANES, BSN, RN OCTOBER 19, 2020 As you stock up your medicine cabinet for the traditional winter “cold and flu season,” you may find yourself wondering if COVID-19 will get worse this winter, too. Probably, yes. As I keep saying, there’s a lot we don’t know about how this virus behaves. But we do know a combination of factors — including human behavior — could lead to a spike of COVID-19 cases throughout the winter months. First, thanks to cold weather, people will get pushed indoors. We know the virus spreads more easily indoors than outdoors, where wind can disperse and blow away the viral particles. So if people decide to beat “quarantine fatigue” by engaging in more indoor activities — like entertaining friends at home or dining out or gathering for the holidays — then we could see a surge of COVID-19 cases. Second, the onset of cold and flu season means more people will ...
- Source: drugdu
- 610
- October 21, 2020
Covid-19 SARS-CoV-2
Remdesivir Doesn’t Reduce COVID-19 Patients’ Risk of Death Study

MONDAY, Oct. 19, 2020 (HealthDay News) — The antiviral drug remdesivir doesn’t reduce COVID-19 patients’ risk of death, a new study says. The World Health Organization-sponsored study of the drug — the only antiviral authorized for treatment of COVID-19 in the United States –included more than 11,000 people in 30 countries, The New York Times reported. The findings were posted online on Thursday, but have not yet been peer-reviewed or published in a scientific journal. “This puts the issue to rest — there is certainly no mortality benefit,” Dr. Ilan Schwartz, an infectious-disease physician at the University of Alberta in Canada, told The Times. However, another infectious-disease expert expressed caution about the findings. A large trial like this that’s conducted in numerous countries with different health care systems can result in inconsistent treatment protocols whose effects can be difficult to analyze, Dr. Peter Chin-Hong, University of California, San Francisco, told ...
- Source: drugdu
- 358
- October 20, 2020
Covid-19
Russia approves a second vaccine

Last month, Russia announced the approval of a COVID-19 vaccine called Sputnik V. This week, President Vladimir Putin announced the approval of a second vaccine, called EpiVacCorona. As with the first, scientists have not yet tested this vaccine in phase 3 trials. The vaccine was developed by scientists at the State Virology and Biotechnology Center, known as Vektor, in Novosibirsk. According to The Moscow Times: “Early trials on 100 volunteers were said to have been successful.” In a televised news conference, Putin explained that researchers had given the vaccine to Deputy Prime Minister Tatyana Golikova and the head of Russia’s consumer safety watchdog, Anna Popova, as part of ongoing trials. During the briefing, they explained that: “Early trials on 100 volunteers were said to have been successful.” As with Sputnik V, experts are likely to view the new vaccine with skepticism. Vaccines must be rigorously investigated before they can be used widely, and ...
- Source: drugdu
- 382
- October 19, 2020
Covid
AI-Enhanced Ultrasound Shortens Scan Time and Improves Efficiency

By MedImaging International staff writers Posted on 14 Oct 2020 Image: Novel AI algorithms power the Voluson SWIFT OB/GYN ultrasound scanner (Photo courtesy of GE Healthcare) A new OB/GYN ultrasound scanner includes artificial intelligence (AI) algorithms that support auto-recognition, high image quality, and efficiency features. The GE Healthcare (GE; Little Chalfont, United Kingdom) Voluson SWIFT ultrasound system includes an embedded AI platform that features SonoLyst, a fully integrated AI tool with a suite of image recognition tools that automatically identify fetal anatomy in over 20 standard views. A scan assistant tool reduces patient scan times by 45% through simplified workflow and personal protocol customization. SonoBiometry measurements, which are 38% faster than in previous platforms, add three measurements that increase system automation by 60%; Additional features include SonoCNS, part of GE’s Edison intelligence platform, that reduces keystrokes for capturing fetal central nervous system (CNS) planes and measurements by 78%; Tricefy, ...
- Source: drugdu
- 194
- October 16, 2020

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.